Pharmchem Stock Revenue
| PCHM Stock | USD 3.05 0.00 0.00% |
PharmChem fundamentals help investors to digest information that contributes to PharmChem's financial success or failures. It also enables traders to predict the movement of PharmChem Pink Sheet. The fundamental analysis module provides a way to measure PharmChem's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PharmChem pink sheet.
PharmChem |
PharmChem Company Revenue Analysis
PharmChem's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current PharmChem Revenue | 26.45 M |
Most of PharmChem's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PharmChem is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, PharmChem reported 26.45 M of revenue. This is 99.65% lower than that of the Health Care Providers & Services sector and 98.66% lower than that of the Health Care industry. The revenue for all United States stocks is 99.72% higher than that of the company.
PharmChem Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PharmChem's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of PharmChem could also be used in its relative valuation, which is a method of valuing PharmChem by comparing valuation metrics of similar companies.PharmChem is currently under evaluation in revenue category among its peers.
PharmChem Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.0537 | |||
| Profit Margin | (0.08) % | |||
| Operating Margin | (0.06) % | |||
| Current Valuation | 17.56 K | |||
| Price To Earning | (2.30) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0006 X | |||
| Revenue | 26.45 M | |||
| Gross Profit | 5.86 M | |||
| Net Income | (2.15 M) | |||
| Cash And Equivalents | 626 K | |||
| Cash Per Share | 0.11 X | |||
| Debt To Equity | 0.37 % | |||
| Current Ratio | 0.69 X | |||
| Book Value Per Share | 1.30 X | |||
| Earnings Per Share | (0.35) X | |||
| Number Of Employees | 11 | |||
| Beta | 1.15 | |||
| Market Capitalization | 17.55 K | |||
| Total Asset | 16.66 M | |||
| Retained Earnings | (10.28 M) | |||
| Working Capital | 1.28 M | |||
| Current Asset | 6.8 M | |||
| Current Liabilities | 5.52 M | |||
| Z Score | 1.0 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 4.60 % | |||
| Net Asset | 16.66 M |
About PharmChem Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PharmChem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PharmChem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PharmChem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in PharmChem Pink Sheet
PharmChem financial ratios help investors to determine whether PharmChem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PharmChem with respect to the benefits of owning PharmChem security.